222 related articles for article (PubMed ID: 24819758)
1. Inflammatory/infectious cutaneous side effects of biological drugs in patients with psoriasis: a general review with personal data.
Rongioletti F; Burlando M; Parodi A
G Ital Dermatol Venereol; 2014 Jun; 149(3):311-6. PubMed ID: 24819758
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.
Puig L; Morales-Múnera CE; López-Ferrer A; Geli C
Dermatology; 2012; 225(1):14-7. PubMed ID: 22890275
[TBL] [Abstract][Full Text] [Related]
3. Prospective new biologic therapies for psoriasis and psoriatic arthritis.
Mortel MR; Emer J
J Drugs Dermatol; 2010 Aug; 9(8):947-58. PubMed ID: 20684145
[TBL] [Abstract][Full Text] [Related]
4. Skin lesions and treatment with tumor necrosis factor alpha antagonists.
Hernández MV; Meineri M; Sanmartí R
Reumatol Clin; 2013; 9(1):53-61. PubMed ID: 22766431
[TBL] [Abstract][Full Text] [Related]
5. New biologics for psoriasis and psoriatic arthritis.
Rozenblit M; Lebwohl M
Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
[TBL] [Abstract][Full Text] [Related]
6. [Infectious risk].
Calabuig E; Salavert M
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
[TBL] [Abstract][Full Text] [Related]
7. Management of patients with psoriasis treated with biological drugs needing a surgical treatment.
Fabiano A; De Simone C; Gisondi P; Piaserico S; Lasagni C; Pellacani G; Conti A
Drug Dev Res; 2014 Nov; 75 Suppl 1():S24-6. PubMed ID: 25381969
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.
Piérard GE; Piérard-Franchimont C; Szepetiuk G; Paquet P; Quatresooz P
Expert Opin Biol Ther; 2010 Aug; 10(8):1197-208. PubMed ID: 20560729
[TBL] [Abstract][Full Text] [Related]
9. Could anti IL12/23 therapy replace anti-TNF biologics?
Ionescu MA; Lipozencić J
Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
[TBL] [Abstract][Full Text] [Related]
10. Injection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis.
Henderson Berg MH; Carrasco D
J Drugs Dermatol; 2017 Jul; 16(7):695-698. PubMed ID: 28697222
[TBL] [Abstract][Full Text] [Related]
11. Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab.
Garcia-Valladares I; Cuchacovich R; Espinoza LR
Drug Des Devel Ther; 2011 Jan; 5():41-9. PubMed ID: 21267358
[TBL] [Abstract][Full Text] [Related]
12. When anti-TNF fails, anti-IL12-23 is an alternate option in psoriasis and psoriatic arthritis.
Golmia RP; Martins AH; Scheinberg M
Rev Bras Reumatol; 2014; 54(3):247-9. PubMed ID: 25054605
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
14. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha?
Cuchacovich R; Espinoza CG; Virk Z; Espinoza LR
J Clin Rheumatol; 2008 Dec; 14(6):353-6. PubMed ID: 19033869
[TBL] [Abstract][Full Text] [Related]
15. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical reactions induced by tumor necrosis factor-alpha antagonists: A literature review based on 46 cases.
Olteanu R; Zota A
Indian J Dermatol Venereol Leprol; 2016; 82(1):7-12. PubMed ID: 26728803
[TBL] [Abstract][Full Text] [Related]
17. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?
Rallis E; Korfitis C; Stavropoulou E; Papaconstantis M
J Dermatolog Treat; 2010 Jan; 21(1):3-5. PubMed ID: 19701844
[TBL] [Abstract][Full Text] [Related]
18. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
Channual J; Wu JJ; Dann FJ
Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
[TBL] [Abstract][Full Text] [Related]
19. Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases.
Prieto-Pérez R; Cabaleiro T; Daudén E; Abad-Santos F
Pharmacogenomics J; 2013 Aug; 13(4):297-305. PubMed ID: 23337970
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis.
Med Lett Drugs Ther; 2014 Feb; 56(1435):10-2. PubMed ID: 24662976
[No Abstract] [Full Text] [Related]
[Next] [New Search]
